From the Research
Seizures in Non-Alcoholic Steatohepatitis (NASH)
There is no direct evidence in the provided studies that links seizures to Non-Alcoholic Steatohepatitis (NASH).
NASH Overview
- NASH is a form of liver disease characterized by steatosis, inflammation, and fibrosis 1, 2, 3, 4, 5
- It is a severe form of Non-Alcoholic Fatty Liver Disease (NAFLD) 1, 2, 3, 5
- The key features that distinguish NASH from non-NASH fatty liver are cellular ballooning, inflammation, and fibrosis 1
NASH Pathogenesis
- The "multiple-hits" hypothesis suggests that fat accumulation, elevated oxidative and ER stress may drive liver inflammation and fibrosis 2
- Insulin resistance, inflammation, and mitochondrial dysfunction are factors that participate in the genesis and progression of NASH 5
- Changes in the pattern of organokines secretion (adipokines, myokines, hepatokines, and osteokines) may contribute to aggravating the condition or compromise homeostasis 5
NASH Treatment and Prognosis
- Currently, no NASH-specific therapies are approved by the US Food and Drug Administration 3
- Lifestyle modification, including dietary changes and exercise, is the mainstay of treatment, with the primary goal being weight loss 3
- Substantial improvement in histologic outcomes, including fibrosis, is directly correlated with increasing weight loss 3
- NASH is predicted to become the leading indication for liver transplants in the US, and patients with NASH have increased risk of developing cirrhosis and liver failure 2, 3